The Louvain Centre for Toxicology and Applied Pharmacology (LTAP) is seeking for an enthusiastic, highly motivated and skilled candidate with a background in toxicology, pathology, tumor biology or immunology for Senior Scientist (post-doctoral) role in our mesothelioma program.
The selected candidate will be focused in work leading to the characterization of mesotheliomagenic macrophages. She/he will effectively collaborate within our research center and supervise young scientists and technicians working in the project.
We offer an inspiring multicultural environment, constructed of our enthusiastic, highly skilled and experienced personnel. LTAP has established working links with local immunologists and medical doctors and other groups from French and American universities. Brussels is a very good city to live in. It offers a safe living environment, cultured atmosphere and a central localization in Europe.
PhD in toxicology, immunology, molecular/cell biology, or cancer biology.
Knowledge on macrophage biology, high-throughput experimentation, large data analysis or lipidomics is positively evaluated.
Strong hands-on technical skills (e.g. primary cell isolation and culture, flow cytometry, live cell imaging).
Effective written and spoken English language skills.
Excellent teamwork skills.
The Université catholique de Louvain (UCLouvain; www.uclouvain.be
) involves more than 30,000 students of 123 different nationalities and a staff of about 5,800 teachers, researchers and administrative and technical collaborators. UCLouvain is ranked first among Belgian francophone universities. Research is one of UCLouvain’s main activities with €242M in annual research and development investment. More than 1000 research contracts are signed every year with universities, public institutions and private companies. UCLouvain is actively involved in 176 projects within FP7 and in already 98 Horizon 2020 projects.
The Louvain Centre for Toxicology and Applied Pharmacology (LTAP, www.toxi.ucl.ac.be/accueil.html
) was established in 2009 at UCLouvain to conduct advanced research on the effects of xenobiotics on human health in IREC. LTAP addresses both intended (applied pharmacology) and adverse health effects of chemicals (toxicology). The centre integrates interdisciplinary expertise (clinical, analytical, experimental, epidemiological sciences) and is actively engaged in commissioned projects and research for European, national and regional government bodies, major companies, trade associations. Our group has broad expertise in studying the toxic mechanisms of inhaled particles and was among the very first worldwide (2005) to report on the respiratory toxicity of multi-walled carbon nanotubes (MWCNT). The Centre is fully equipped and has expertise to conduct human and clinical studies. LTAP combines wide experience in research and publishing with youthful flair and imagination. We published 244 papers between 2014 and 2018 (44 of which in journals with an impact factor >5). Over the same period, research expenditures reached 3.225.000 euros.